Shots:
- Kali Therapeutics has entered into a license agreement with Sanofi for KT501 to treat a broad range of B cell-mediated autoimmune diseases
- As per the deal, Sanofi will obtain exclusive worldwide rights to KT501, while Kali will receive upfront & near-term payments totaling $180M and up to $1.05B in development & commercial milestones, with tiered royalties on sales ranging from the high-single to double digits
- KT501 is a tri-specific T-cell engager that is being evaluated in a FIH study to assess its safety, tolerability, PK & PD in pts with Rheumatoid Arthritis
Ref: PRnewswire | Image: Kali Therapeutics &Sanofi | Press Release
Related News: Sino Biopharmaceutical and Sanofi Partner to Advance Rovadicitinib in a ~$1.53B Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
